Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Associated Therapies: -

Clinical Trials

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Phase 3

Active, not recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: HS-10296

First Posted Date: 2019-02-21

Last Posted Date: 2023-01-20

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 429

Registration Number: NCT03849768

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Not Applicable

Conditions: Non-Small-Cell Lung

Interventions: Drug: Anlotinib Hydrochloride
Drug: Gefitinib
Drug: Icotinib

First Posted Date: 2018-12-06

Last Posted Date: 2019-01-30

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 66

Registration Number: NCT03766490

Locations: 🇨🇳
The First Affiliated hospital of soochow university, Suzhou, Jangsu, China

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Phase 1

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: CT053PTSA
Drug: Gefitinib

First Posted Date: 2018-11-29

Last Posted Date: 2022-06-22

Lead Sponsor: Sunshine Lake Pharma Co., Ltd.

Target Recruit Count: 158

Registration Number: NCT03758287

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma

Phase 3

Conditions: NSCLC
EGFR

Interventions: Drug: Vinorelbine
Drug: Gefitinib
Drug: Carboplatin

First Posted Date: 2018-09-04

Last Posted Date: 2018-09-04

Lead Sponsor: Shenzhen People's Hospital

Target Recruit Count: 48

Registration Number: NCT03656393

Locations: 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients with Central Nervous System (CNS) Metastases

Phase 2

Completed

Conditions: EGFR Gene Mutation
Non-small Cell Lung Cancer
Brain Metastases

Interventions: Drug: AZD3759
Drug: Erlotinib
Drug: Gefitinib

First Posted Date: 2018-08-31

Last Posted Date: 2024-10-15

Lead Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd.

Target Recruit Count: 492

Registration Number: NCT03653546

Locations: 🇨🇳
China site, Tianjin, China
🇨🇳
China site 0123, Jinan, Shandong, China
🇰🇷
Korea Site, Seoul, Korea, Republic of

and more 3 locations

Phase I Study of the Combination of Anlotinib With Gefitinib

Not Applicable

Conditions: Non-squamous Non-small Cell Lung Cancer

Interventions: Drug: Anlotinib
Drug: Gefitinib

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Second Affiliated Hospital of Nanchang University

Target Recruit Count: 9

Registration Number: NCT03602027

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: DS-1205c
Drug: Gefitinib

First Posted Date: 2018-07-26

Last Posted Date: 2023-02-08

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT03599518

Locations: 🇯🇵
Aichi Cancer Center, Chikusa, Aichi, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Kindai University Hospital, Sayama, Osaka, Japan

and more 5 locations

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Phase 2

Conditions: Lung Adenocarcinoma
EGFR Mutation

Interventions: Drug: gefitinib
Drug: Berberine

First Posted Date: 2018-04-03

Last Posted Date: 2018-04-03

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT03486496

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Phase 2

Conditions: Advanced NSCLC With EGFR Mutation

Interventions: Drug: S-1 plus Gefitinib
Drug: Gefitinib

First Posted Date: 2018-03-07

Last Posted Date: 2020-07-10

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT03457337

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: gefitinib

First Posted Date: 2018-01-16

Last Posted Date: 2018-01-16

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 100

Registration Number: NCT03399669

Locations: 🇰🇷
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy